A Dolcera Report production about production of therapeutic proteins by glycosylation, major players and technological developments. The report focuses on technology, industry and patent landscape of the concerned topic. The Dolcera center of excellence finds about growth of a technology; competition- key players, innovators; gaps and opportunities in the technology and industry with the analyses of patents and trends as the core. This presentation is a brief introduction to the detailed Dolcera Report on production of therapeutic proteins by glycosylation. For more details and complete report contact info@dolcera.com

1. Production of Therapeutic
Knowledge Services
Glycoproteins
Production of Therapeutic
info@dolcera.com Glycoproteins

2. Like this presentation?
This is only a sample report with brief analysis. Purchase the complete
report here. Price: $999
Dolcera can provide a comprehensive report customized to your needs
Buy the customized report from Dolcera
Patent Analytics Services Market Research Services Purchase Patent Dashboard
Patent Landscape Services Dolcera Processes Industry Focus
Patent Search Services Patent Alerting Services Dolcera Tools
Samir Raiyani
Email: info@dolcera.com
Phone: +1-650-425-6772
Fax: +1-866-690-7517
info@dolcera.com Production of Therapeutic 2
Glycoproteins

3. Contents
Production of Therapeutic Glycoproteins
Introduction
IP search
Taxonomy
Top Cited Patents
Patent to product mapping
Key Findings
• Major Players
• IP Activity
• Geographical Activity
•Categorization on the basis of production
method - Top assignees under each category
Technology citation statistics
Assignee citation statistics
info@dolcera.com Production of Therapeutic 3
Glycoproteins

4. Introduction
• Glycosylation is the attachment of a carbohydrate group to a protein, catalyzed by
enzymes called glycosyl transferases.
• The majority of clinically approved protein drugs bear some form of post-
translational modification, most commonly glycosylation.
• Glycosylation is important because it can influence the therapeutic efficacy,
immunogenicity, solubility, and in-vivo half life of the glycoprotein.
• Glycosylation has been found to occur in a large variety of protein classes,
including – but not limited to – antibodies, protein hormones, growth factors,
cytokines and vaccines.
• Several systems used for the production of proteins in glycosylated form are being
explored. Some of these include Mammalian systems like CHO, fungal systems,
insects, plants, bacterial systems etc. Glycosylated proteins are also being
produced by in vitro means.
info@dolcera.com Production of Therapeutic 4
Glycoproteins

5. Taxonomy
A detailed taxonomy is
presented, which was
obtained after a sample
analysis. It includes
various hosts, systems,
process and utilities of
protein glycosylation
• To see the detailed VVT Taxonomy, mailto: info@dolcera.com
info@dolcera.com Production of Therapeutic 5
Glycoproteins

6. Classification
• Different classes related to glycosylated therapeutics and production of
therapeutics that can be glycosylated are identified.
• These Classes are used in the search strategy
• To see the detailed classification, mailto: info@dolcera.com
info@dolcera.com Production of Therapeutic 6
Glycoproteins

7. Control Patents
• Highly relevant patents are used for extracting keywords and ensuring the
quality of the search query
• To see the detailed table, mailto: info@dolcera.com
info@dolcera.com Production of Therapeutic 7
Glycoproteins

8. Search Concepts
• Concepts used to search patent literature
• Relevant keywords were also translated to French and German to
search for French and German language patents
• To see the detailed table, mailto: info@dolcera.com
info@dolcera.com Production of Therapeutic 8
Glycoproteins

9. IP Search
Database: Thomson Innovation
Timeline: 01-01-1991 to 30-08-2011
• To see the detailed table, mailto: info@dolcera.com
info@dolcera.com Production of Therapeutic 9
Glycoproteins

10. Patent to product mapping
• The patens are mapped to the products based on patent focus
info@dolcera.com Production of Therapeutic 10
Glycoproteins

11. Dolcera Dashboard
• Dolcera dashboard is a web 2.0 technology. It enables dynamic
presentation of patent data
info@dolcera.com Production of Therapeutic 11
Glycoproteins

12. Insights: Major Players
• Roche Holding Ltd, Kirin Holdings Company Limited and Novo Nordisk are the top
assignees in the field
info@dolcera.com Production of Therapeutic 12
Glycoproteins

13. Insights: Key Patents
• The key patents in the area are held by University of California, University of
Texas, Alko Inc and Bristol-Myers Squibb Co.
info@dolcera.com Production of Therapeutic 13
Glycoproteins

14. Insights: Year wise IP activity
• Year wise IP activity based on publication years
info@dolcera.com Production of Therapeutic 14
Glycoproteins

15. Insights: Year wise IP activity
• Year wise IP activity based on priority years
info@dolcera.com Production of Therapeutic 15
Glycoproteins

16. Insights: Geographical Distribution
• Geographical distribution of patents
info@dolcera.com Production of Therapeutic 16
Glycoproteins

17. Insights: Major Player – Mammalian cell lines
• Roche holding Ltd., Kirin Holdings Co.Ltd. and Lonza Group AG are active in using
mammalian cell lines
info@dolcera.com Production of Therapeutic 17
Glycoproteins

18. Insights: Major Player – Transgenic Animals
• Abbott Lab. Leads in using transgenic animals
info@dolcera.com Production of Therapeutic 18
Glycoproteins

19. Insights: Major Player - Plants
• Dow Chemical Co. and Plant Research International lead in plant systems
info@dolcera.com Production of Therapeutic 19
Glycoproteins

20. Insights: Major Player - Microorganisms
• Merck & Co. Inc, Kirin Holdings Co. Ltd. and Novozymes AS lead in microbial
systems
info@dolcera.com Production of Therapeutic 20
Glycoproteins

21. Insights: Major Player - Enzymes
• Novo Nordisk, Kirin Holdings Co.Ltd. and Roche Holding Ltd. lead in using enzyme
systems
info@dolcera.com Production of Therapeutic 21
Glycoproteins

22. Insights: Major Player – Chemical/Cell free synthesis
• Novo Nordisk, Roche Holding Ltd. and Otsuka Holding Co. Ltd. lead in
chemical/cell free synthesis systems
info@dolcera.com Production of Therapeutic 22
Glycoproteins

23. Insights: Major Player: Fermentation/Culture conditions
• Roche Holding Ltd., Pfizer Inc. and Bristol Myers Squibb Co. lead in
fermentation/culture conditions
info@dolcera.com Production of Therapeutic 23
Glycoproteins

24. Conclusions
• The first generation of biopharmaceuticals manufactured using recombinant
technologies was launched in the 1980s, and patents protecting them are now nearing
expiration. As with small molecule drugs, the expiration of patents creates an
opportunity for generic biologicals to enter the market. Current IP situation allows a
new patent protection of the product and the process
• CHO is the most preferred system for production of proteins with mammalian type
glycosylation.
• Due to drawbacks in mammalian systems, active research is on to find alternate
production systems for producing glycoproteins. Few such hosts include E.coli, Yeast,
Fungi, plants and insect systems.
• A few patents also talk on chemical/cell free synthesis for in vitro protein glycosylation.
info@dolcera.com Production of Therapeutic 24
Glycoproteins

25. Like this presentation?
This is only a sample report with brief analysis. Purchase the complete
report here. Price: $999
Dolcera can provide a comprehensive report customized to your needs
Buy the customized report from Dolcera
Patent Analytics Services Market Research Services Purchase Patent Dashboard
Patent Landscape Services Dolcera Processes Industry Focus
Patent Search Services Patent Alerting Services Dolcera Tools
Samir Raiyani
Email: info@dolcera.com
Phone: +1-650-425-6772
Fax: +1-866-690-7517
info@dolcera.com Production of Therapeutic 25
Glycoproteins